• Product NameTalazoparib (BMN 673)
• Brief DescriptionInhibitors
• Purification99.69%
• Biological ActivityTalazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.58 nM. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
• Target NamePARP inhibitor
• CAS No. 1207456-01-6
• Calculated MW 380.35
• Formulation C19H14F2N6O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
  Pathways:Chromatin/Epigenetic; DNA Damage/DNA Repair
  Receptor:PARP
  Boling pt:
  Melting pt:
  Solubility:DMSO:38 mg/mL warmed (99.9 mM)Ethanol:<1 mg/mL (<1 mM)Water<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Wang B, et al. Molecular Cancer Therapeutics, 2009, 8 (12 Suppl), A121.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting